RET

    OverviewSuggest Edit

    We are a Peruvian enterprise that exports organic textile products to companies, institutions and others who are interested in the productions of solely responsible organic material non-harmful to the environment.

    The products we make are inspired in a sustainable development, this being the principal factor in our client's needs and the environment. We believe that sustainability is accomplished by quality, through safety, durability and utility.

    Our main goal is to fulfill our social, environmental and economic responsibility, and we hope that through our products help our customers to enable them to fulfill theirs too.

    TypePrivate
    Founded2012
    HQDistrito de Lima, PE
    Websiteret.pe

    RET Office Locations

    RET has an office in Distrito de Lima
    Distrito de Lima, PE (HQ)
    125 Tejada
    Show all (1)

    RET Financials and Metrics

    Summary Metrics

    Founding Date

    2012

    RET Online and Social Media Presence

    Embed Graph

    RET News and Updates

    Lilly's targeted RET drug shrinks tumors in lung cancer trial

    Eli Lilly and Co's LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.

    Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

    INDIANAPOLIS, Sept. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive non-small...

    Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor

    CARLSBAD, Calif., Sept. 9, 2019 /PRNewswire/ -- Thermo Fisher Scientific today announced an agreement with Eli Lilly and Company for development of a companion diagnostic that will use the U.S Food and Drug Administration-approved, next-generation sequencing-based Oncomine Dx Target Test...

    Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors

    RALEIGH, N.C. and SHANGHAI, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (“XRI”) has successfully designed a series of potent RET kina…

    Competitive Range Solutions Appoints Lt. Gen. Ronnie D. Hawkins Jr. (USAF Ret.) to Board of Advisors

    ​Competitive Range Solutions announced today that it has appointed Former First Commander of the Joint Force Headquarters - Department of Defense Information Networks (DoDIN) Lt. Gen. Ronnie D. Hawkins Jr. (USAF Retired) to Board of Advisors.

    RET Ventures leads seed round for Slingshot

    Orem, Utah-based Slingshot, a customer engagement platform for home services providers, has raised $2.4 million in seed funding. RET Ventures led the round.
    Show more

    RET Frequently Asked Questions

    • When was RET founded?

      RET was founded in 2012.

    • Who are RET competitors?

      Competitors of RET include Furniweb, Coats and Carnegie.

    • Where is RET headquarters?

      RET headquarters is located at 125 Tejada, Distrito de Lima.

    • Where are RET offices?

      RET has an office in Distrito de Lima.

    • How many offices does RET have?

      RET has 1 office.